RxDoctor Payments Data

Hang Munsayac, MD

Internal Medicine · Houston, TXNPI 1538314331

Payments from drug & device makers

$1,210in general payments, 2019–2025

Across 63 payments — averaging $19.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$308
  • AstraZeneca$128
  • Amgen$118
  • Bayer$99
  • Lilly USA, LLC$73
  • AbbVie$56
  • plus $428 from 14 others

What the payments were for

  • Food & beverage$1,210100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,210 in reported general payments places this provider in the 70th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$174,489
Medicare patients
422
Services billed
1,972

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate22$33,774
FarxigaDapagliflozin Propanediol19$18,924
OzempicSemaglutide14$13,770
TradjentaLinagliptin12$10,057
SynthroidLevothyroxine Sodium114$9,419
Breo ElliptaFluticasone/Vilanterol21$8,351
Levothyroxine Sodium296$3,464
Atorvastatin Calcium298$3,276
Rosuvastatin Calcium152$2,712
Ezetimibe56$2,702
Metoprolol Succinate122$2,598
Pravastatin Sodium165$2,434
Losartan Potassium167$2,109
Amlodipine Besylate259$1,790
Gabapentin97$1,544

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$55$33,77422 claims
AstraZenecaFarxiga$128$18,92419 claims
Novo NordiskOzempic$308$13,77014 claims
Boehringer IngelheimTradjenta$16$10,05712 claims
AbbVieSynthroid$56$9,419114 claims
GSKBreo Ellipta$21$8,35121 claims
PfizerPaxlovid$18$1,42916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →